MedDay Pharmaceuticals has announced new top-line data showing that its experimental drug MD1003 missed the primary and secondary endpoints of the Phase III SPI2 trial.
MedDay Pharmaceuticals announced full enrollment of SPI2, a phase III clinical trial designed to confirm the potential of its investigational drug MD1003 in progressive MS as shown in MS-SPI phase III trial.